serous cystadenocarcinoma

Summary

Summary: A malignant cystic or semicystic neoplasm. It often occurs in the ovary and usually bilaterally. The external surface is usually covered with papillary excrescences. Microscopically, the papillary patterns are predominantly epithelial overgrowths with differentiated and undifferentiated papillary serous cystadenocarcinoma cells. Psammoma bodies may be present. The tumor generally adheres to surrounding structures and produces ascites. (From Hughes, Obstetric-Gynecologic Terminology, 1972, p185)

Top Publications

  1. Herrington C, McCluggage W. The emerging role of the distal Fallopian tube and p53 in pelvic serous carcinogenesis. J Pathol. 2010;220:5-6 pubmed publisher
    ..In addition to its biological significance, this, if proven, has clear clinical implications...
  2. Yang Y, Hou J, Qu L, Wang G, Ju H, Zhao Z, et al. [Differential expression of USP2, USP14 and UBE4A between ovarian serous cystadenocarcinoma and adjacent normal tissues]. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2007;23:504-6 pubmed
    The differential expression of USP2, USP14 and UBE4A between ovarian serous cystadenocarcinoma and adjacent normal tissues was investigated.
  3. Hirst J, Gard G, McIllroy K, Nevell D, Field M. High rates of occult fallopian tube cancer diagnosed at prophylactic bilateral salpingo-oophorectomy. Int J Gynecol Cancer. 2009;19:826-9 pubmed publisher
    ..It supports emerging evidence that the fimbrial end of the fallopian tube is an important site of genesis of cancer in BRCA1/2 mutation carriers. ..
  4. King J, Ng T, White S, Cortina G, Reber H, Hines O. Pancreatic serous cystadenocarcinoma: a case report and review of the literature. J Gastrointest Surg. 2009;13:1864-8 pubmed publisher
    Serous cystic neoplasms of the pancreas are benign lesions with little chance for malignant degeneration. We report a case of malignant serous cystadenocarcinoma of the pancreas and review the literature.
  5. Jarboe E, Folkins A, Nucci M, Kindelberger D, Drapkin R, Miron A, et al. Serous carcinogenesis in the fallopian tube: a descriptive classification. Int J Gynecol Pathol. 2008;27:1-9 pubmed
    ..Combined with recent reports associating STICs with pelvic serous cancer, this continuum of epithelial change validates the SCAT sequence and the fimbrial secretory cell as the site of origin for many serous carcinomas...
  6. Folkins A, Jarboe E, Roh M, Crum C. Precursors to pelvic serous carcinoma and their clinical implications. Gynecol Oncol. 2009;113:391-6 pubmed publisher
    ..The data supporting a candidate precursor, the implications of these findings for early detection and prevention of pelvic serous carcinoma and the caveats, are discussed...
  7. Levanon K, Crum C, Drapkin R. New insights into the pathogenesis of serous ovarian cancer and its clinical impact. J Clin Oncol. 2008;26:5284-93 pubmed publisher
    ..With the rise of the fallopian tube secretory epithelial cell as a cell of origin for high-grade pelvic serous carcinomas, the need to develop tools and model systems to characterize the biology and physiology of this cell is recognized...
  8. Huang Y, Hua K, Zhou X, Jin H, Chen X, Lu X, et al. Activation of the PI3K/AKT pathway mediates FSH-stimulated VEGF expression in ovarian serous cystadenocarcinoma. Cell Res. 2008;18:780-91 pubmed publisher
    ..We further showed that ovarian serous cystadenocarcinoma samples had much higher incidence of positive AKT and phosphorylated AKT (pAKT) protein staining than ..
  9. Nam E, Yoon H, Kim S, Kim H, Kim Y, Kim J, et al. MicroRNA expression profiles in serous ovarian carcinoma. Clin Cancer Res. 2008;14:2690-5 pubmed publisher
    ..We assessed the expression of microRNA and the association between microRNA expression and the prognosis of serous ovarian carcinoma...

More Information

Publications85

  1. Partheen K, Levan K, Osterberg L, Claesson I, Fallenius G, Sundfeldt K, et al. Four potential biomarkers as prognostic factors in stage III serous ovarian adenocarcinomas. Int J Cancer. 2008;123:2130-7 pubmed publisher
    ..According to our results, the 4 biomarkers CLU, ITGB3, PRAME and CAPG may be used as prognostic factors for patients with stage III serous ovarian adenocarcinomas...
  2. Lomo L, Nucci M, Lee K, Lin M, Hirsch M, Crum C, et al. Histologic and immunohistochemical decision-making in endometrial adenocarcinoma. Mod Pathol. 2008;21:937-42 pubmed publisher
    ..Because p53 is an important marker for endometrial adenocarcinoma outcome, and cannot be predicted in advance in indeterminate cases, p53 immunostaining should be employed in cases with observer disagreement in a binary system...
  3. Tetu B, Popa I, Bairati I, L Esperance S, Bachvarova M, Plante M, et al. Immunohistochemical analysis of possible chemoresistance markers identified by micro-arrays on serous ovarian carcinomas. Mod Pathol. 2008;21:1002-10 pubmed publisher
    ..61; CI: 0.94-2.79; P=0.08). Our study shows that gene expression analysis coupled with immunohistochemistry allowed the identification of HSP10 as an independent factor of progression-free survival...
  4. Wong K, Lu K, Malpica A, Bodurka D, Shvartsman H, Schmandt R, et al. Significantly greater expression of ER, PR, and ECAD in advanced-stage low-grade ovarian serous carcinoma as revealed by immunohistochemical analysis. Int J Gynecol Pathol. 2007;26:404-9 pubmed
    ..These differences may lead to the development of different therapeutic strategies for women with either the low-grade or the high-grade form of OSC...
  5. Salani R, Kurman R, Giuntoli R, Gardner G, Bristow R, Wang T, et al. Assessment of TP53 mutation using purified tissue samples of ovarian serous carcinomas reveals a higher mutation rate than previously reported and does not correlate with drug resistance. Int J Gynecol Cancer. 2008;18:487-91 pubmed
    ..3%, which is much higher than previously reported. Furthermore, we found that TP53 is not directly involved in the development of drug resistance in high-grade ovarian serous carcinomas...
  6. Jia L, Liu Y, Yi X, Miron A, Crum C, Kong B, et al. Endometrial glandular dysplasia with frequent p53 gene mutation: a genetic evidence supporting its precancer nature for endometrial serous carcinoma. Clin Cancer Res. 2008;14:2263-9 pubmed publisher
    ..The purpose of this study is to determine if EmGD is genetically linked to ESC and if it can be used for early detection...
  7. Thomas M, Mariani A, Cliby W, Keeney G, Podratz K, Dowdy S. Role of cytoreduction in stage III and IV uterine papillary serous carcinoma. Gynecol Oncol. 2007;107:190-3 pubmed
    ..Uterine papillary serous carcinoma (UPSC) frequently presents in advanced stages. The aim of this study was to assess the role of cytoreduction in stage IIIC-IV UPSC...
  8. Plaxe S. Epidemiology of low-grade serous ovarian cancer. Am J Obstet Gynecol. 2008;198:459.e1-8; discussion 459.e8-9 pubmed publisher
    ..The objective of the study was to determine whether the epidemiology of low-grade ovarian serous cancers is distinct from that of high-grade ovarian serous cancers...
  9. Jordan S, Green A, Whiteman D, Moore S, Bain C, Gertig D, et al. Serous ovarian, fallopian tube and primary peritoneal cancers: a comparative epidemiological analysis. Int J Cancer. 2008;122:1598-603 pubmed
    ..These results also call into question the role of the physical effects of ovulation in the development of serous ovarian cancer...
  10. Vang R, Shih I, Kurman R. Ovarian low-grade and high-grade serous carcinoma: pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems. Adv Anat Pathol. 2009;16:267-82 pubmed publisher
    ..This review provides an update on the pathogenesis and clinicopathologic features of these 2 types of serous carcinomas and addresses some of the diagnostic problems that are encountered in routine practice...
  11. Salvador S, Rempel A, Soslow R, Gilks B, Huntsman D, Miller D. Chromosomal instability in fallopian tube precursor lesions of serous carcinoma and frequent monoclonality of synchronous ovarian and fallopian tube mucosal serous carcinoma. Gynecol Oncol. 2008;110:408-17 pubmed publisher
    ..Recent studies suggest these cancers may arise in the fallopian tube. This study explores the relationship between ovarian cancers and fallopian tube mucosal involvement...
  12. Köbel M, Huntsman D, Gilks C. Critical molecular abnormalities in high-grade serous carcinoma of the ovary. Expert Rev Mol Med. 2008;10:e22 pubmed publisher
    ..These highly aggressive but chemosensitive tumours are associated with perturbation of molecular pathways leading to genomic instability and extreme mutability and present unique challenges in oncological research and practice...
  13. Kuo K, Mao T, Jones S, Veras E, Ayhan A, Wang T, et al. Frequent activating mutations of PIK3CA in ovarian clear cell carcinoma. Am J Pathol. 2009;174:1597-601 pubmed publisher
    ..We therefore suggest that the use of PIK3CA-targeting drugs may offer a more effective therapeutic approach compared with current chemotherapeutic agents for patients with advanced-stage and recurrent CCC...
  14. Dehari R, Kurman R, Logani S, Shih I. The development of high-grade serous carcinoma from atypical proliferative (borderline) serous tumors and low-grade micropapillary serous carcinoma: a morphologic and molecular genetic analysis. Am J Surg Pathol. 2007;31:1007-12 pubmed
    ..The above results suggest that the majority of high-grade and low-grade carcinomas develop independently but in rare cases, a high-grade serous carcinoma may arise from an atypical proliferative serous (borderline) tumor...
  15. Tong G, Chiriboga L, Hamele Bena D, Borczuk A. Expression of PAX2 in papillary serous carcinoma of the ovary: immunohistochemical evidence of fallopian tube or secondary Müllerian system origin?. Mod Pathol. 2007;20:856-63 pubmed
  16. Galanis C, Zamani A, Cameron J, Campbell K, Lillemoe K, Caparrelli D, et al. Resected serous cystic neoplasms of the pancreas: a review of 158 patients with recommendations for treatment. J Gastrointest Surg. 2007;11:820-6 pubmed
    ..Serous cystic neoplasms of the pancreas are regarded as a benign entity with rare malignant potential. Surgical resection is generally considered curative...
  17. Lee Y, Miron A, Drapkin R, Nucci M, Medeiros F, Saleemuddin A, et al. A candidate precursor to serous carcinoma that originates in the distal fallopian tube. J Pathol. 2007;211:26-35 pubmed
  18. Silva E, Gershenson D, Malpica A, Deavers M. The recurrence and the overall survival rates of ovarian serous borderline neoplasms with noninvasive implants is time dependent. Am J Surg Pathol. 2006;30:1367-71 pubmed
    ..We propose that patients be followed for a minimum of 10 years to evaluate for recurrences and for 20 years to evaluate for survival...
  19. Biade S, Marinucci M, Schick J, Roberts D, Workman G, Sage E, et al. Gene expression profiling of human ovarian tumours. Br J Cancer. 2006;95:1092-100 pubmed
    ..The data that we have generated will contribute to a growing body of expression data that more accurately define the biologic and clinical characteristics of ovarian cancers...
  20. Zorn K, Bonome T, Gangi L, Chandramouli G, Awtrey C, Gardner G, et al. Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer. Clin Cancer Res. 2005;11:6422-30 pubmed
    ..This study compares the gene expression profiles of analogous histologic subtypes of cancers of the ovary and endometrium using the same genomic platform to determine the similarities and differences between these tumors...
  21. Terauchi F, Okamoto A, Nagashima T, Kobayashi Y, Moritake T, Yamamoto Y, et al. Clinical significance of p21(WAF1/CIP1) and p53 expression in serous cystadenocarcinoma of the ovary. Oncol Rep. 2005;14:363-8 pubmed
  22. Shintaku M, Arimoto A, Sakita N. Serous cystadenocarcinoma of the pancreas. Pathol Int. 2005;55:436-9 pubmed
    A case of serous cystadenocarcinoma of the pancreas in an 85-year-old woman is reported. The tumor extensively involved the body and tail of the pancreas and contiguously invaded the spleen...
  23. Friebe V, Keck T, Mattern D, Schmitt Graeff A, Werner M, Mikami Y, et al. Serous cystadenocarcinoma of the pancreas: management of a rare entity. Pancreas. 2005;31:182-7 pubmed
    ..case of an 80-year-old woman with a primary tumor of the pancreas that was histologically classified as serous cystadenocarcinoma. Because preoperatively available criteria that determine malignancy in serous lesions are lacking, ..
  24. Marquez R, Baggerly K, Patterson A, Liu J, Broaddus R, Frumovitz M, et al. Patterns of gene expression in different histotypes of epithelial ovarian cancer correlate with those in normal fallopian tube, endometrium, and colon. Clin Cancer Res. 2005;11:6116-26 pubmed
    ..This study compares gene expression in serous, endometrioid, clear cell, and mucinous ovarian cancers with that in the normal tissues that they resemble...
  25. Bonome T, Lee J, Park D, Radonovich M, Pise Masison C, Brady J, et al. Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary. Cancer Res. 2005;65:10602-12 pubmed
    ..Prominent expression of p53 pathway members may play an important role in the LMP tumor phenotype...
  26. Le T, Shahriari P, Hopkins L, Faught W, Fung Kee Fung M. Prognostic significance of tumor necrosis in ovarian cancer patients treated with neoadjuvant chemotherapy and interval surgical debulking. Int J Gynecol Cancer. 2006;16:986-90 pubmed
    ..97, 95% CI 1.01-3.87, P= 0.048). The estimated median survival was 50.66 months (95% CI 46.12-55.20). The lack of or minimal tumor necrosis after neoadjuvant chemotherapy is an independent risk factor for recurrent disease...
  27. Dansonka Mieszkowska A, Ludwig A, Kraszewska E, Kupryjanczyk J. Geographical variations in TP53 mutational spectrum in ovarian carcinomas. Ann Hum Genet. 2006;70:594-604 pubmed
    ..002), while tumours from the UK shared the 273(CYS) codon (80%, p < 0.001). Further analysis of TP53 gene mutations in ovarian cancer by geography could provide greater insights...
  28. Partheen K, Levan K, Osterberg L, Horvath G. Expression analysis of stage III serous ovarian adenocarcinoma distinguishes a sub-group of survivors. Eur J Cancer. 2006;42:2846-54 pubmed
    ..Alternative chemotherapy strategies could then be offered as first-line treatment, which may lead to improvements in the clinical outcome for these patients...
  29. Kindelberger D, Lee Y, Miron A, Hirsch M, Feltmate C, Medeiros F, et al. Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: Evidence for a causal relationship. Am J Surg Pathol. 2007;31:161-9 pubmed
  30. Buerke B, Heindel W, Wessling J. [Differential diagnosis and radiological management of cystic pancreatic lesions]. Rofo. 2010;182:852-60 pubmed publisher
  31. Casadei R, Ricci C, Zanini N, Marrano N, Pezzilli R, Minni F. Laparoscopic distal pancreatectomy in non-malignant pancreatic tumors. JOP. 2008;9:71-3 pubmed
  32. Fader A, Starks D, Gehrig P, Secord A, Frasure H, O Malley D, et al. An updated clinicopathologic study of early-stage uterine papillary serous carcinoma (UPSC). Gynecol Oncol. 2009;115:244-8 pubmed publisher
    ..Given that current clinicopathologic data does not accurately identify women most likely to benefit from adjuvant therapy, alternative prognostic markers based on novel techniques should be explored. ..
  33. Fader A, von Gruenigen V, Gibbons H, Abushahin F, Starks D, Markman M, et al. Improved tolerance of primary chemotherapy with reduced-dose carboplatin and paclitaxel in elderly ovarian cancer patients. Gynecol Oncol. 2008;109:33-8 pubmed publisher
    ..Age, performance status and other geriatric parameters should be considered when dosing chemotherapy in the elderly. ..
  34. Melhem A, Yamada S, Fleming G, Delgado B, Brickley D, Wu W, et al. Administration of glucocorticoids to ovarian cancer patients is associated with expression of the anti-apoptotic genes SGK1 and MKP1/DUSP1 in ovarian tissues. Clin Cancer Res. 2009;15:3196-204 pubmed publisher
    ..This finding supports the hypothesis that pharmacologic doses of glucocorticoids may decrease chemotherapy effectiveness in ovarian cancer patients through increased anti-apoptotic gene expression. ..
  35. Tiro A, Talukdar R, Lewis M. A unique case of serous psammocarcinoma of the ovary presenting with pleural effusion and manifesting psammoma body implants in the pleural cavity and pericardium. Gynecol Oncol. 2009;113:402-4 pubmed publisher
    ..Psammomatous carcinoma is rare, with few cases having been reported to date...
  36. Song T, Zhang Z, Liu L, Yang T, Jiang J, Li P. Small interfering RNA-mediated silencing of heat shock protein 27 (HSP27) Increases chemosensitivity to paclitaxel by increasing production of reactive oxygen species in human ovarian cancer cells (HO8910). J Int Med Res. 2009;37:1375-88 pubmed
    ..The siRNA-induced knock-down of HSP27 could be a novel and potent strategy to help overcome chemotherapeutic resistance to paclitaxel in epithelial ovarian cancer cells. ..
  37. Han L, Pansare V, Al Abbadi M, Husain M, Feng J. Combination of MUC5ac and WT-1 immunohistochemistry is useful in distinguishing pancreatic ductal carcinoma from ovarian serous carcinoma in effusion cytology. Diagn Cytopathol. 2010;38:333-6 pubmed publisher
    ..It appears that the combination of MUC5ac and WT-1 stains is useful in distinguishing pancreatic ductal from ovarian serous carcinoma in body fluid cytology...
  38. Pon Y, Zhou H, Cheung A, Ngan H, Wong A. p70 S6 kinase promotes epithelial to mesenchymal transition through snail induction in ovarian cancer cells. Cancer Res. 2008;68:6524-32 pubmed publisher
    ..These results indicate that p70(S6K) may play a critical role in tumor progression in ovarian cancer through the induction of EMT. Targeting p70(S6K) may thus be a useful strategy to impede cancer cell invasion and metastasis. ..
  39. Garcia P, Manterola C, Araya J, Villaseca M, Guzman P, Sanhueza A, et al. Promoter methylation profile in preneoplastic and neoplastic gallbladder lesions. Mol Carcinog. 2009;48:79-89 pubmed publisher
    ..Finally, the methylation status of some individual genes could be useful biomarkers with potential clinical application in diagnosis or prognosis of GBC if they are validated in a greater number of clinical samples. ..
  40. Anderson K, Wong J, Vitonis A, Crum C, Sluss P, Labaer J, et al. p53 autoantibodies as potential detection and prognostic biomarkers in serous ovarian cancer. Cancer Epidemiol Biomarkers Prev. 2010;19:859-68 pubmed publisher
    ..Although their utility as a preoperative diagnostic biomarker, beyond CA 125 and HE4, is limited, p53-AAb are prognostic for improved overall survival. ..
  41. Marverti G, Ligabue A, Guerrieri D, Paglietti G, Piras S, Costi M, et al. Spermidine/spermine N1-acetyltranferase modulation by novel folate cycle inhibitors in cisplatin-sensitive and -resistant human ovarian cancer cell lines. Gynecol Oncol. 2010;117:202-10 pubmed publisher
    ..Recent studies showed that the thymidylate synthase inhibitor 5-fluorouracil (5-FU) affects polyamine metabolism in colon carcinoma cells through the induction of the key catabolic enzyme spermidine/spermine N1-acetyltransferase (SSAT)...
  42. Partheen K, Levan K, Osterberg L, Claesson I, Sundfeldt K, Horvath G. External validation suggests Integrin beta 3 as prognostic biomarker in serous ovarian adenocarcinomas. BMC Cancer. 2009;9:336 pubmed publisher
    ..The loss of ITGB3 expression in tumours from deceased patients and high expression in tumours from survivors could be used as a biomarker for patients with advanced serous tumours. ..
  43. Watari H, Hosaka M, Mitamura T, Moriwaki M, Ohba Y, Todo Y, et al. Weekly paclitaxel/5-fluorouracil followed by platinum retreatment for patients with recurrent ovarian cancer: a single institution experience. Eur J Gynaecol Oncol. 2008;29:573-7 pubmed
    ..We need to establish the standard treatment strategy for recurrent ovarian cancer patients with a poor prognosis. ..
  44. Zhang S, Zhou X, Yu H, Yu Y. Expression of tumor-specific antigen MAGE, GAGE and BAGE in ovarian cancer tissues and cell lines. BMC Cancer. 2010;10:163 pubmed publisher
    ..6% (2/7) and 14.3% (1/7). The positive expression rates of MAGE-1 and MAGE-3 in serous cystadenocarcinoma were significantly higher than that in other types of ovarian cancer (P < 0.05)...
  45. Choi Y, Kim J, Kwon M, Choi J, Kim T, Bae D, et al. Expression profile of tight junction protein claudin 3 and claudin 4 in ovarian serous adenocarcinoma with prognostic correlation. Histol Histopathol. 2007;22:1185-95 pubmed publisher
    ..Our findings suggest that CLDN3 overexpression can be used as a prognostic indicator in ovarian serous carcinomas. Moreover, CLDN3 may be a promising target for antibody-based therapy of ovarian carcinomas. ..
  46. Signorelli M, Lissoni A, Cormio G, Katsaros D, Pellegrino A, Selvaggi L, et al. Modified radical hysterectomy versus extrafascial hysterectomy in the treatment of stage I endometrial cancer: results from the ILIADE randomized study. Ann Surg Oncol. 2009;16:3431-41 pubmed publisher
  47. Kane A, Uzan C, Rey A, Gouy S, Duvillard P, Morice P. Secondary surgery in patients with serous low malignant potential ovarian tumors with peritoneal implants. Int J Gynecol Cancer. 2010;20:346-52 pubmed publisher
    ..Patients with residual disease are probably those likely to benefit from such surgery. Further studies are needed to confirm these preliminary results. ..
  48. Matsuura T, Sugihara K, Kohmura Y, Sugimura H, Kanayama N. Rare form of extraovarian peritoneal serous papillary carcinoma with solitary tumor in the abdominal wall: a case report and literature review. J Obstet Gynaecol Res. 2009;35:1142-7 pubmed publisher
    ..This is an extremely rare case of serous papillary adenocarcinoma with a cystic tumor that was categorized as extraovarian peritoneal serous papillary carcinoma (EPSPC) without other clinical findings. ..
  49. Hemalatha A, Rao S, Kumar D, Vani M. Papillary serous carcinoma of the broad ligament: a rare case report. Indian J Pathol Microbiol. 2007;50:555-7 pubmed
    ..The highlight of this case is that besides being a rare tumor occurring in an unusual site such as the broad ligament the papillary serous carcinoma reported here also has a unique feature of transitional cell differentiation...
  50. Kuhn E, Meeker A, Wang T, Sehdev A, Kurman R, Shih I. Shortened telomeres in serous tubal intraepithelial carcinoma: an early event in ovarian high-grade serous carcinogenesis. Am J Surg Pathol. 2010;34:829-36 pubmed publisher
  51. Cross S, Cocco E, Bellone S, Anagnostou V, Brower S, Richter C, et al. Differential sensitivity to platinum-based chemotherapy in primary uterine serous papillary carcinoma cell lines with high vs low HER-2/neu expression in vitro. Am J Obstet Gynecol. 2010;203:162.e1-8 pubmed publisher
    ..Higher proliferative capability rather than increased drug resistance may be responsible for the adverse prognosis associated with HER-2/neu overexpression in USPC. ..
  52. Stawerski P, Wagrowska Danilewicz M, Stasikowska O, Gottwald L, Danilewicz M. Immunoexpression of beta-catenin--E-cadherin complex in primary serous ovarian tumors. Pol J Pathol. 2008;59:27-32 pubmed
    ..In conclusion, our data suggest that decreased immunoexpression of beta-catenin and E-cadherin in serous ovarian tumors may be helpful in identifying the cases of higher metastatic potential and infiltration ability. ..
  53. Kanayama S, Yamada Y, Haruta S, Naruse K, Furukawa N, Kawaguchi R, et al. Peritoneal disseminated recurrence and lung metastasis after surgery for stage IA uterine papillary serous carcinoma of the endometrium: a case report. Arch Gynecol Obstet. 2008;278:277-80 pubmed publisher
    ..We describe a case of synchronous peritoneal dissemination and multiple lung metastases after surgery for stage IA primary uterine papillary serous carcinoma (UPSC) of the endometrium, revealed by an uncontrollable retention of ascites...
  54. Camci C, Sevinc A, Aslan Y, Kalender M, Buyukberber S. Complete remission of platinium refractory ovarian cancer with second line tegafur with uracil monotherapy: a case report. Cancer Chemother Pharmacol. 2009;63:745-8 pubmed publisher
  55. Cho K. Ovarian cancer update: lessons from morphology, molecules, and mice. Arch Pathol Lab Med. 2009;133:1775-81 pubmed publisher
    ..It is expected that these mouse models will yield new insights into ovarian cancer pathogenesis and prove useful for preclinical testing of novel strategies for ovarian cancer treatment...
  56. Li C, Zota V, Woda B, Rock K, Fraire A, Jiang Z, et al. Expression of a novel oncofetal mRNA-binding protein IMP3 in endometrial carcinomas: diagnostic significance and clinicopathologic correlations. Mod Pathol. 2007;20:1263-8 pubmed
    ..In addition, expression of IMP3 in endometrioid adenocarcinoma correlates with higher nuclear and architecture grades of the tumor (P=0.0000 and P=0.0002, respectively)...
  57. Sanguedolce F, Indraccolo U, Tortorella S, Nappi L, Rosenberg P, Greco P, et al. A case of ovarian psammocarcinoma associated with endometrioid cysts: a morphological and immunohistochemical study. Tumori. 2009;95:112-4 pubmed
    ..Psammocarcinoma of the ovary is an uncommon neoplasm, currently classified among the low-grade epithelial serous tumors. Little is known about its pathogenesis and biological behavior...
  58. Markman M. Diagnostic evaluations of unproven clinical utility in oncology: a real-life example of their harmful consequences. Curr Oncol Rep. 2008;10:271-2 pubmed
  59. Fujiwara K, Nagao S, Kigawa J, Noma J, Akamatsu N, Miyagi Y, et al. Phase II study of intraperitoneal carboplatin with intravenous paclitaxel in patients with suboptimal residual epithelial ovarian or primary peritoneal cancer: a Sankai Gynecology Cancer Study Group Study. Int J Gynecol Cancer. 2009;19:834-7 pubmed publisher
    ..Large-scale phase III trial comparing with IV carboplatin is warranted in this patient population. ..
  60. Vang R, Shih I, Salani R, Sugar E, Ayhan A, Kurman R. Subdividing ovarian and peritoneal serous carcinoma into moderately differentiated and poorly differentiated does not have biologic validity based on molecular genetic and in vitro drug resistance data. Am J Surg Pathol. 2008;32:1667-74 pubmed publisher
    ..Accordingly, they can be simply classified as high-grade serous carcinoma...
  61. Pantanowitz L, Otis C, Goulart R. Cytologic findings of psammocarcinoma in peritoneal washings. Acta Cytol. 2009;53:263-7 pubmed
  62. Shechter Maor G, Bruchim I, Ben Harim Z, Altaras M, Fishman A. Combined chemotherapy regimen of carboplatin and paclitaxel as adjuvant treatment for papillary serous and clear cell endometrial cancer. Int J Gynecol Cancer. 2009;19:662-4 pubmed publisher
    ..The regimen of carboplatin and paclitaxel is active in patients with UPSC and UCCC with an acceptable toxicity profile. ..
  63. Xian W, Miron A, Roh M, Semmel D, Yassin Y, Garber J, et al. The Li-Fraumeni syndrome (LFS): a model for the initiation of p53 signatures in the distal Fallopian tube. J Pathol. 2010;220:17-23 pubmed publisher
    ..This is in keeping with a general model of carcinogenesis, in which different and often independent risk factors operate at multiple points in the serous carcinogenic spectrum...
  64. Fotiou S, Aliki T, Petros Z, Ioanna S, Konstantinos V, Vasiliki M, et al. Secondary cytoreductive surgery in patients presenting with isolated nodal recurrence of epithelial ovarian cancer. Gynecol Oncol. 2009;114:178-82 pubmed publisher
    ..To evaluate the role of secondary cytoreductive surgery in the management of patients with isolated nodal recurrence of epithelial ovarian cancer...
  65. Chi D, Barlin J, Ramirez P, Levenback C, Mironov S, Sarasohn D, et al. Follow-up study of the correlation between postoperative computed tomographic scan and primary surgeon assessment in patients with advanced ovarian, tubal, or peritoneal carcinoma reported to have undergone primary surgical cytoreduction to residual . Int J Gynecol Cancer. 2010;20:353-7 pubmed publisher
    ..Discordant findings between the primary surgeon's assessment and the postoperative CT scan findings of residual disease was not an independent prognostic factor. ..
  66. Köbel M, Kalloger S, Huntsman D, Santos J, Swenerton K, Seidman J, et al. Differences in tumor type in low-stage versus high-stage ovarian carcinomas. Int J Gynecol Pathol. 2010;29:203-11 pubmed publisher
    ..These findings reflect important biological differences in the behavior of the major tumor types, with important clinical implications...
  67. Kajiyama H, Shibata K, Terauchi M, Ino K, Nawa A, Kikkawa F. Involvement of SDF-1alpha/CXCR4 axis in the enhanced peritoneal metastasis of epithelial ovarian carcinoma. Int J Cancer. 2008;122:91-9 pubmed
    ..The present results suggest that there may be a link between the SDF-1alpha/CXCR4 axis and enhanced intraperitoneal dissemination of EOC and that CXCR4 may be a novel target for the treatment of EOC...
  68. Tsukioka M, Matsumoto Y, Noriyuki M, Yoshida C, Nobeyama H, Yoshida H, et al. Expression of glucose transporters in epithelial ovarian carcinoma: correlation with clinical characteristics and tumor angiogenesis. Oncol Rep. 2007;18:361-7 pubmed
    ..These findings suggest that characteristic differences in the patterns of glucose uptake can exist according to the histological type and that GLUT1, GLUT3 and GLUT4 could be related to tumor angiogenesis in epithelial ovarian carcinoma...
  69. Wong K, Gershenson D. The continuum of serous tumors of low malignant potential and low-grade serous carcinomas of the ovary. Dis Markers. 2007;23:377-87 pubmed
    ..This review summarizes the current clinical, genetic, and genomic evidence for the existence of a continuum comprising both LMP serous tumors and low-grade serous ovarian carcinomas...
  70. Farghaly S. Metastasis-associated genes profile in ovarian serous papillary carcinomas. Am J Obstet Gynecol. 2007;197:555; author reply 555-6 pubmed
  71. Lax S. [Serous genital carcinoma: molecular pathogenesis and the role of tubal fimbria]. Pathologe. 2009;30 Suppl 2:210-6 pubmed publisher
    ..Since an advanced tumor stage is frequent and often makes the determination of the origin impossible, the term pelvic serous carcinoma was recently proposed for high grade serous (adeno)carcinomas involving multiple sites...
  72. Bapat S, Krishnan A, Ghanate A, Kusumbe A, Kalra R. Gene expression: protein interaction systems network modeling identifies transformation-associated molecules and pathways in ovarian cancer. Cancer Res. 2010;70:4809-19 pubmed publisher
    ..In the parlance of this emerging field, such networks of gene-hub interactions may define personalized therapeutic decisions...
  73. Yang G, Rosen D, Liu G, Yang F, Guo X, Xiao X, et al. CXCR2 promotes ovarian cancer growth through dysregulated cell cycle, diminished apoptosis, and enhanced angiogenesis. Clin Cancer Res. 2010;16:3875-86 pubmed publisher
    ..Chemokine receptor CXCR2 is associated with malignancy in several cancer models; however, the mechanisms involved in CXCR2-mediated tumor growth remain elusive. Here, we investigated the role of CXCR2 in human ovarian cancer...
  74. Rath K, Funk H, Bowling M, Richards W, Drew A. Expression of soluble interleukin-6 receptor in malignant ovarian tissue. Am J Obstet Gynecol. 2010;203:230.e1-8 pubmed publisher
    ..The objective of the study was to investigate interleukin-6 receptor (IL6R) isoforms and sheddases in the ovarian tumor microenvironment...
  75. Feng W, Marquez R, Lu Z, Liu J, Lu K, Issa J, et al. Imprinted tumor suppressor genes ARHI and PEG3 are the most frequently down-regulated in human ovarian cancers by loss of heterozygosity and promoter methylation. Cancer. 2008;112:1489-502 pubmed publisher
    ..Two imprinted genes, paternally expressed 3 (PEG3) and aplasia Ras homologue member I (ARHI), are the most frequently down-regulated in ovarian cancers on gene expression arrays...
  76. Deavers M. Immunohistochemistry in gynecologic pathology. Arch Pathol Lab Med. 2008;132:175-80 pubmed publisher
    ..The following case studies are used to illustrate the value of some relatively new markers in the diagnosis of gynecologic neoplasms and to highlight potential diagnostic pitfalls...